Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 17023
Country/Region: South Africa
Year: 2016
Main Partner: BroadReach Healthcare
Main Partner Program: South Africa
Organizational Type: NGO
Funding Agency: USAID
Total Funding: $19,952,015 Additional Pipeline Funding: $2,099,861

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $3,580,136
Care: TB/HIV (HVTB) $1,935,566
Care: Pediatric Care and Support (PDCS) $730,378
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $960,756
Treatment: Adult Treatment (HTXS) $12,014,801
Treatment: Pediatric Treatment (PDTX) $730,378
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 34,074
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 22,722
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 193,148
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 128,767
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 378,711
HTS_TST Service Delivery Point (Facility): Inpatient 2017 4,366
HTS_TST Service Delivery Point (Facility): Outpatient 2017 197,944
HTS_TST Service Delivery Point (Facility): Pediatric 2017 53,140
HTS_TST Service Delivery Point (Facility): PMTCT 2017 123,261
HTS_TST Sum of Aggregated Age/Sex <15 2017 56,796
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 321,915
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 378,711
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 4,306
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 2,863
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 24,327
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 16,221
PMTCT_ART Already on ART at beginning of current pregnancy 2017 10,905
PMTCT_ART New on ART 2017 7,264
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 83,093
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 18,169
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 165
PMTCT_EID Sum of Infant Age disaggregates 2017 18,169
PMTCT_STAT By: Known positives at entry 2017 33,244
PMTCT_STAT By: Number of new positives identified 2017 49,849
PMTCT_STAT Number of new ANC and L&D clients 2017 84,793
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 83,093
PMTCT_STAT Sum of Positives Status disaggregates 2017 83,093
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 1,195
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 6,833
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 811
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 4,543
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 14,867
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 13,382
TB_SCREENDX [Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 11,961
TB_SCREENDX [Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert) 2017 616
TB_SCREENDX [Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only 2017 1,190
TB_SCREENDX [Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 10,156
TB_SCREENDX Screen Results: Screened Positive for TB 2017 13,241
TB_SCREENDX Screened for TB by Age/Sex: <15 Female 2017 47,834
TB_SCREENDX Screened for TB by Age/Sex: <15 Male 2017 31,889
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 271,049
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 180,707
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 531,479
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 2,233
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 12,629
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 1,494
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 8,430
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 24,786
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 26,084
TX_CURR Aggregated Age/Sex: <15 Female 2017 46,662
TX_CURR Aggregated Age/Sex: <15 Male 2017 31,122
TX_CURR Aggregated Age/Sex: 15+ Female 2017 264,480
TX_CURR Aggregated Age/Sex: 15+ Male 2017 176,311
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 518,575
TX_CURR Sum of Aggregated Age/Sex <15 2017 77,784
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 440,791
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 518,575
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 8,560
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 5,712
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 48,516
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 32,336
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 95,124
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 95,124
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 466,714
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 420,038
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 37,791
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 25,213
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 214,228
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 142,806
TX_PVLS Numerator: Indication: Routine 2017 378,027
TX_PVLS Numerator: Indication: Targeted 2017 42,011
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 42,008
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 27,996
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 238,041
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 158,676
TX_PVLS_den Denominator: Indication: Routine 2017 420,069
TX_PVLS_den Denominator: Indication: Targeted 2017 46,672
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 43,868
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 29,245
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 248,617
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 165,734
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 487,464
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 599,426
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 53,946
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 35,966
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 305,710
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 203,804
Cross Cutting Budget Categories and Known Amounts Total: $4,793,999
Human Resources for Health $4,193,999
Motor Vehicles: Leased $600,000